AHA Scientific Sessions 2025 Abstract

VANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial of weekly subcutaneous administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes

By Karen M. Modesto, Karen Chung, Summer Ji, Brian Lian

Trial in peopleInterventions

The paper

Karen M. Modesto, Karen Chung, Summer Ji, Brian Lian

Viking Therapeutics (United States)

AHA Scientific Sessions 2025 Abstract, 3 Nov 2025

Presented at AHA Scientific Sessions 2025, abstract 4367152

doi.org/10.1161/circ.152.suppl_3.4367152

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety